BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//pretalx//sciencenext.org//DZLSRZ
BEGIN:VTIMEZONE
TZID:EET
BEGIN:STANDARD
DTSTART:20001029T030000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10;UNTIL=20061029T000000Z
TZNAME:EET
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
END:STANDARD
BEGIN:STANDARD
DTSTART:20071028T050000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10;UNTIL=20141026T020000Z
TZNAME:EET
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
END:STANDARD
BEGIN:STANDARD
DTSTART:20151108T050000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYMONTH=11;UNTIL=20151108T020000Z
TZNAME:EET
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
END:STANDARD
BEGIN:STANDARD
DTSTART:20160907T010000
RRULE:FREQ=YEARLY;BYDAY=1WE;BYMONTH=9
TZNAME:+03
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20000326T020000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3;UNTIL=20060326T000000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20070325T040000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3;UNTIL=20100328T020000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20110328T040000
RRULE:FREQ=YEARLY;BYDAY=4MO;BYMONTH=3;UNTIL=20110328T020000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20120325T040000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3;UNTIL=20130331T020000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20140331T040000
RRULE:FREQ=YEARLY;BYDAY=5MO;BYMONTH=3;UNTIL=20140331T020000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20150329T040000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3;UNTIL=20160327T020000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
UID:pretalx-ifos2026-DZLSRZ@sciencenext.org
DTSTART;TZID=EET:20260910T073000
DTEND;TZID=EET:20260910T080000
DESCRIPTION:<p style="margin-left: 0px!important\;">Head and neck squamous 
 cell carcinoma (HNSCC) is the seventh most common cancer worldwide. In the
  oral cavity\, most cases of squamous cell carcinoma begin as a precursor 
 lesion classified by the World Health Organization (WHO) as an “oral pot
 entially malignant disorder (OPMD).” Oral leukoplakia is the most common
  OPMD\, with a global prevalence of 4.1% and a malignant transformation ra
 te between 0.1%-34.0%\, and the malignant transformation rate increases to
  40% in oral dysplasia. These wide ranges of malignant transformation rate
 s suggest an unmet need to develop prognostic biomarkers that can better d
 ifferentiate benign from premalignant lesions and predict the risk of tran
 sformation of premalignant lesions to invasive cancer. To address this maj
 or knowledge gap\, the NIDCR partnered with the NCI Early Detection Resear
 ch Network (EDRN) to bring together leading investigators to form a nation
 al network of Advancing Head and Neck Cancer Early Detection Research (AHE
 AD). In this session\, we will highlight the efforts and advancements made
  in the field of early-stage detection and prevention of head and neck can
 cers. The learning objectives for the session are to: a) Review the curren
 t standard of care for patients diagnosed with OPMD\; b) Identify the curr
 ent challenges in diagnosing oral premalignant disease and\; c) Explain th
 ree methodological and technological approaches being investigated for the
  early detection and prevention of HPV-positive and HPV-negative head and 
 neck cancers.</p>
DTSTAMP:20260618T234916Z
LOCATION:Head & Neck Surgery 3
SUMMARY:Early-Stage Detection and Prevention of Head and Neck Cancers - Sar
 a Pai
URL:https://sciencenext.org/ifos2026/talk/DZLSRZ/
END:VEVENT
END:VCALENDAR